As a scientist, Kevin Lustig saw firsthand how pharmaceutical research can soar into the hundreds of billions of dollars while progress remains painfully slow – the U.S. Food and Drug Administration approved only 46 drugs last year. As an entrepreneur, he saw an opportunity open for the taking.